AbVacc - BOARD OF DIRECTORS

Board of Directors

AbVacc works closely with a team of highly experienced scientists at its parent company, IBT, a Board of Directors composed of seasoned experts in vaccine manufacturing and development, and a Scientific Advisory Board comprising many of the leading clinicians and basic science experts in the field of S. aureus immunology and clinical management.

Michael Hodges, M.D.

Michael is a highly experienced and successful pharmaceutical industry veteran. He has worked on eight drug development programs in big PHARMA as the team leader/team member that has led to global regulatory approvals. Within biotech, he has been part of teams that have raised Series B and C rounds of financing (~$150MM), one F-1 submission for IPO, one reverse merger, and two successful M&As. He has deep disease-specific and RNA therapeutics technical expertise. He is currently supporting a number of Biotechnology companies in the role of drug development consultant, scientific advisor, and/or board director. He is a member of the science advisory boards of Arcturus Therapeutics, Exicure Therapeutics, and eFFECTOR Therapeutics and a scientific advisor for Adjuvant Capital.

Clement Lewin, Ph.D., MBA.

Clement Lewin is a Principal at CSL Vaccine Consulting with expertise in medical affairs, policy, and strategy. Until the end of 2020, he headed the BARDA Office and NV Stakeholder Engagement for Sanofi Pasteur where he played an instrumental role in securing and managing over $2 billion in BARDA funding for pandemic influenza and COVID-19 vaccines development as well as serving as one of the external spokespeople for the COVID-19 program.

Dr. Bruce Forrest, M.D.

Dr. Bruce Forrest serves as the President of Hudson Innovations, LLC, and as Co-Head of Life Sciences Investment Banking, Young America Capital, LLC. Dr. Forrest received his MD at the University of Adelaide, Australia, in 1991. He possesses over 25 years of global leadership in pharmaceutical development with expertise in, but not limited to, vaccines and biopharmaceuticals development in both major and emerging markets.

Javad Aman, Ph.D.

Dr. Aman is a molecular immunologist and corporate executive with over 30 years of experience in the field of immunology, microbiology, and vaccine and immunotherapeutics development for infectious diseases. Dr. Aman founded Integrated BioTherapeutics (IBT) and grew the business, now a clinical-stage company, and raised over $120M in non-dilutive funding. In 2023 Dr. Aman spun off AbVacc from IBT to focus on structure-guided design of vaccine and immunotherapeutics. He graduated from the school of Pharmacy at the University of Frankfurt in 1990.